Research Progress on the Microenvironment and Immunotherapy of Advanced Non-Small Cell Lung Cancer With Liver Metastases

Fang, Yujia; Su, Chunxia

doi:10.3389/fonc.2022.893716

Cited by 8 publications

(11 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Immune checkpoint inhibitor monotherapy and combination therapy have made breakthrough progress in advanced non-small cell lung cancer (NSCLC) patients. Furthermore, compared with the overall population, the liver metastases population was an independent prognostic factor for poor immunotherapy response (20). It is well known that patients who respond to ICI tend to develop irAEs (5).…”

Section: Discussionmentioning

confidence: 98%

Construction and evaluation of clinical prediction model for immunotherapy-related adverse events and clinical benefit in cancer patients receiving immune checkpoint inhibitors based on serum cytokine levels

Zhao

Jiang

Shang

et al. 2023

Preprint

View full text Add to dashboard Cite

Background: Immune checkpoint inhibitors (ICIs) have revolutionized the therapeutic landscape of cancer. The aim of this study was to develop novel risk classifiers to predict the risk of irAEs and probability of clinical benefits of these individuals. Methods: The cancer patients received ICIs from the First Affiliated Hospital of Xi 'an Jiaotong University from November 2020 to October 2022 were collected and followed up. The logistic regression analyses were adopted to identify independent predictive factors of irAEs and clinical response. Two nomograms were developed to predict the irAEs and clinical response of these individuals, with receiver operating characteristic curve (ROC) and calibration curve being generated to assess their predictive ability. Besides, decision curve analysis (DCA) was performed to estimate the clinical utility of the nomograms. Results: This study included 583 cancer patients from 2434 cancer patients. Among them, 111 patients (19.0%) developed irAEs. The multivariate analysis indicated that duration of treatment (DOT)＞3 cycles, Hepatic-metastases, IL2＞2.225pg/ml, and IL8＞7.39pg/ml were correlated with higher irAEs risk. Overall, 347 patients were included in the final efficacy analysis, with an overall clinical benefit rate of 39.7% being observed. The multivariate analysis indicated that DOT＞3cycles, non-hepatic-metastases, irAEs and IL8＞7.39pg/ml were independent predictive factors of clinical benefit. Ultimately, two nomograms were successfully established to predict the probability of irAEs and clinical benefits. ROC curves yield acceptable performance of nomograms. Calibration curves showed satisfying consistencies between actual and predicted probability. DCA supported that the nomograms could provide more significant net clinical benefits to these patients. Conclusion: Specific baseline serum cytokines are closely correlated to irAEs and clinical response in these individuals. We established two nomograms that could effectively predict the risk of irAEs and probability of clinical response by integration of common clinicopathological parameters and serumcytokines.

show abstract

Section: Discussionmentioning

confidence: 98%

Construction and evaluation of clinical prediction model for immunotherapy-related adverse events and clinical benefit in cancer patients receiving immune checkpoint inhibitors based on serum cytokine levels

Zhao

Jiang

Shang

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…Furthermore, compared with the overall population, liver metastasis is an independent prognostic factor of poor immunotherapy response. 20 It is established that patients who respond to ICI tend to develop irAEs. 5 Kimimasa presented a case of laparoscopic hepatectomy after receiving lenvatinib plus pembrolizumab, in which the patient developed hypothyroidism and hypopituitarism after surgery; the patient was treated with ICIs and responded effectively to ICI therapy before surgery.…”

Section: Discussionmentioning

confidence: 99%

“…Immune checkpoint inhibitor monotherapy and combination therapy have made breakthroughs in patients with NSCLC. Furthermore, compared with the overall population, liver metastasis is an independent prognostic factor of poor immunotherapy response 20 . It is established that patients who respond to ICI tend to develop irAEs 5 .…”

Section: Discussionmentioning

confidence: 99%

Construction and Evaluation of Clinical Prediction Model for Immunotherapy-related Adverse Events and Clinical Benefit in Cancer Patients Receiving Immune Checkpoint Inhibitors Based on Serum Cytokine Levels

Zhao

Jiang

Shang

et al. 2023

Journal of Immunotherapy

View full text Add to dashboard Cite

Immune checkpoint inhibitors (ICIs) have revolutionized the therapeutic landscape of cancer therapy. This study aimed to develop novel risk classifiers to predict the risk of immune-related adverse events (irAEs) and the probability of clinical benefits. Patients with cancer who received ICIs from the First Affiliated Hospital of Xi 'an Jiaotong University from November 2020 to October 2022 were recruited and followed up. Logistic regression analyses were performed to identify independent predictive factors for irAEs and clinical response. Two nomograms were developed to predict the irAEs and clinical responses of these individuals, with a receiver operating characteristic curve to assess their predictive ability. Decision curve analysis was performed to estimate the clinical utility of the nomogram. This study included 583 patients with cancer. Among them, 111 (19.0%) developed irAEs. Duration of treatment (DOT) > 3 cycles, hepatic-metastases, IL2 > 2.225 pg/mL, and IL8 > 7.39 pg/mL were correlated with higher irAEs risk. A total of 347 patients were included in the final efficacy analysis, with an overall clinical benefit rate of 39.7%. DOT > 3 cycles, nonhepatic-metastases, and irAEs and IL8 > 7.39 pg/mL were independent predictive factors of clinical benefit. Ultimately, 2 nomograms were successfully established to predict the probability of irAEs and their clinical benefits. Ultimately, 2 nomograms were successfully established to predict the probability of irAEs and clinical benefits. The receiver operating characteristic curves yielded acceptable nomogram performance. Calibration curves and decision curve analysis supported the hypothesis that nomograms could provide more significant net clinical benefits to these patients. Specific baseline plasma cytokines were closely correlated with irAEs and clinical responses in these individuals.

show abstract

“…[2] Liver is a common site of NSCLC metastasis, affecting approximately 20% of NSCLC patients. [3] Liver metastasis (LM) can modulate systemic immune responses, [4] leading to a poor prognosis. Patients with LM demonstrate a median overall survival (OS) of 3-4 months, [5] which is worse than that of patients with metastases in other organs, including the brain (7 months), bone (6 months), and lymph nodes.…”

Section: Introductionmentioning

confidence: 99%

Evolving landscape of treatments targeting the microenvironment of liver metastases in non-small cell lung cancer

Zhu,

Yu,

Tang

et al. 2024

Chinese Medical Journal

View full text Add to dashboard Cite

Liver metastases (LMs) are common in lung cancer. Despite substantial advances in diagnosis and treatment, the survival rate of patients with LM remains low as the immune-suppressive microenvironment of the liver allows tumor cells to evade the immune system. The impact of LMs on the outcomes of immune checkpoint inhibitors in patients with solid tumors has been the main focus of recent translational and clinical research. Growing evidence indicates that the hepatic microenvironment delivers paracrine and autocrine signals from non-parenchymal and parenchymal cells. Overall, these microenvironments create pre- and post-metastatic conditions for the progression of LMs. Herein, we review the epidemiology, physiology, pathology and immunology, of LMs associated with non-small cell lung cancer and the role and potential targets of the liver microenvironment in LM in each phase of metastasis. Additionally, we reviewed the current treatment strategies and challenges that should be overcome in preclinical and clinical investigations. These approaches target liver elements as the basis for future clinical trials, including combinatorial interventions reported to resolve hepatic immune suppression, such as immunotherapy plus chemotherapy, immunotherapy plus radiotherapy, immunotherapy plus anti-angiogenesis therapy, and surgical resection.

show abstract

Research Progress on the Microenvironment and Immunotherapy of Advanced Non-Small Cell Lung Cancer With Liver Metastases

Cited by 8 publications

References 60 publications

Construction and evaluation of clinical prediction model for immunotherapy-related adverse events and clinical benefit in cancer patients receiving immune checkpoint inhibitors based on serum cytokine levels

Construction and evaluation of clinical prediction model for immunotherapy-related adverse events and clinical benefit in cancer patients receiving immune checkpoint inhibitors based on serum cytokine levels

Construction and Evaluation of Clinical Prediction Model for Immunotherapy-related Adverse Events and Clinical Benefit in Cancer Patients Receiving Immune Checkpoint Inhibitors Based on Serum Cytokine Levels

Evolving landscape of treatments targeting the microenvironment of liver metastases in non-small cell lung cancer

Contact Info

Product

Resources

About